Mobilise-D Technical Validation Study

  • Research type

    Research Study

  • Full title

    Validating digital mobility assessment using wearable technology – The Mobilise-D Technical Validation study.

  • IRAS ID

    270519

  • Contact name

    Lynn Rochestor

  • Contact email

    lynn.rochester@newcastle.ac.uk

  • Sponsor organisation

    The Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 6 months, 0 days

  • Research summary

    Summary of Research

    The Mobilise-D Technical Validation Study is part of the EU-funded IMI project Mobilise-D. This project aims to link digital assessments of mobility to clinical outcomes for regulatory and clinical endorsement. This study comprises the first phase of this project and aims to carry out a technical validation of a device/algorithm pair to measure real-world walking speed and other digital mobility outcomes. The study is an observational design that will compare free-living gait speed and other digital outcomes against reference standards. The usability and acceptability of the devise from perspective of participants and researchers will also be evaluated.

    120 participants representing the disease cohorts of interest to MOBILISE-D partners will be recruited from six different groups: Chronic Obstructive Pulmonary Disease (COPD), Parkinson’s disease (PD), Multiple Sclerosis (MS), Proximal femoral fracture (PFF), Congestive Heart Failure (CHF) and healthy older adults (HA). Participants will be recruited from five clinical sites who have access to the populations of interest and have the capability to conduct technical studies and recruit the participants.

    The protocol includes: a) walking in a gait laboratory under both strictly controlled conditions and under simulated daily activities; b) unsupervised recording of a few hours of real-world daily activities in the participants own home/community; and c) seven days of unsupervised monitoring and interview follow-up to assess participant acceptability and compliance.

    During a) and b), gold-standard technologies will be used which will include the optimal combination of sensors appropriate for each setting. The accuracy of the device/algorithm pair to measure real-world walking speed and other digital mobility outcomes will be established by comparison to the gold-standard to determine criterion validity of the digital outcomes. Wearability and compliance will be addressed using a combination of quantitative and qualitative techniques, including System Usability Scale and semi-structured interviews with users.

    Summary of Results

    What we knew:
    The ability to move is important for well being. Ageing and chronic disease can lead to a loss of mobility and independence. In order to treat, diagnose and monitor mobility loss, we need tools that can detect and measure mobility. Existing measures (based on self-reporting and one-off tests) are limited as they do not sufficiently reflect real-life mobility. A new approach is needed to accurately measure how people move in their usual daily lives. Wearable technology (body worn sensors) has the potential to revolutionise how we assess mobility.

    What we planned to do:
    This study aimed to develop an accurate assessment of mobility using body worn sensors. This required the development of an algorithm which can transform signals from a sensor into a meaningful measure of mobility. We also aimed to understand patient views of this assessment.

    Who we included:
    The study recruited healthy older adults, as well as adults diagnosed with five conditions which are known to affect mobility. A total of 108 participants were included from five clinical sites across Europe (in UK, Germany and Israel). Participants with varying ages and levels of mobility were included in the study.

    What was done:
    Each participant completed three steps of data collection. Step One (Laboratory): Participants completed a range of walking tasks in a clinical laboratory. During these tasks, participants wore a single sensor and a multi-component system of sensors attached to their body and shoes. Their movement was recorded using motion capture cameras (laboratory reference system). Step Two (Real-world): Participants were instructed to wear the single sensor on their lower back for nine days while undertaking their usual daily activities. A mobile phone was provided to track their location. Step Three (Home): Participants were asked to complete a 2.5 hour measurement of unsupervised activities (e.g. walking up/down stairs and moving between rooms) in the home. During this time, participants wore the single sensor and the same multi-component sensor system (home reference system) that was used in the laboratory. Participants were asked about their experience of wearing the single sensor and their use of wearable technology.

    What we found:
    As expected, the data collected showed differences in the way people move in the laboratory compared to the real-world. This confirms the limitation of existing methods of measuring mobility, and highlights the need for a real-world assessment of mobility. The graph shows that participants walk slower in the home than in the laboratory.
    The data collected in this study included a large number of distinct walking periods and a wide range of walking speeds across all participant groups. This is what we expect to see in the real-world, and therefore the data could be used to test our algorithms.
    In this study, data collected from the laboratory and the home reference systems were compared against the data from the single sensor. Walking speed data (our primary outcome measure) was investigated to identify the best performing algorithm with the lowest error in real-life conditions.
    We also tested algorithms looking at other measures of mobility (e.g. rhythm) which are clinically important to the specific patient groups involved.
    As the algorithm showed very promising results, with an acceptable level of error when compared to the reference systems, this can now be used with the single sensor to confidently detect and measure mobility in the real-world. This will allow further exploration of how we move in everyday life, and is the focus in the next stage of the project.

    How patients found it:
    An important aspect of this study was to understand whether this method of measuring mobility is acceptable to patients. Participants spoke about their experiences, and completed questionnaires about the comfort and acceptability of the device.
    Participants reported that the sensor was comfortable. Specifically, using the Comfort Rating Scale Questionnaire, they reported low levels of discomfort with an average score of 1.4 out of 20.
    Acceptability levels were high with an average score of 4.3 out 5 (questionnaire developed by Rabinovich et al., 2013). Participants said they didn’t realise the device was on them once they put it on.
    Some participants were initially concerned that it might be intrusive to wear due to its size, but once they put it on, they didn’t notice it during their daily activities. They were very open to the idea of using a wearable sensor to monitor their condition and felt that any tool which would help their clinician to understand more about their condition would be useful. However, they were not yet sure exactly how it might help as this is still a new method. There were very few fears relating to privacy as participants trusted both researchers and clinicians to manage their information safely.

    What’s next:
    This algorithm developed in this study is now being used in the second phase of the Mobilise-D project – the Clinical Validation Study. This is a larger clinical study (2400 participants) which is investigating the ability of the sensor and algorithm to measure and predict relevant clinical outcomes. These include a general measure of disability, as well as condition-specific outcomes: fall frequency (Parkinson’s Disease and Multiple Sclerosis), occurrence of exacerbation (Chronic Obstructive Pulmonary Disease), and admission to care home (hip fracture).
    The next step will be to engage with regulators to obtain approval for the use of our assessment of mobility in clinical trials and clinical practice. For more information about the wider Mobilise-D project and what we aim to achieve, please visit our website: https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbZoTw3rfK2onZ-2BnZsp-2BALDzniwyTPqoOWAFoZPq5E9hLOAoo_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YLIdM-2B2XjVj5neBMZUlu-2B5Zw9aq2uBXmb7ABLic93S4-2F6k8ZycRPSBkZQpEBfmvZmOaHOc2Esk-2FQTeyR38154hltFmJ-2B2S9dAOpI0OnQXA6KE0zmVZ1TtLmA6YHohXvGRk6tzcwn-2BV62JOtPM682v6RDhcxhr2Wkjk7BVx8faVopg-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7Cafc55d712f4043e4331e08dad223f41a%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638053349101787874%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=ol0kTeyfazezxrOI7SoKUTClVIj8zRgKKr2vbsigBjI%3D&reserved=0

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    19/LO/1507

  • Date of REC Opinion

    11 Nov 2019

  • REC opinion

    Further Information Favourable Opinion